The End of Dual Therapy with Renin-Angiotensin-Aldosterone System Blockade?
N Engl J Med. 2013 Nov 9;
Authors: de Zeeuw D
Abstract
Treatment aimed at multiple risk factors and specific markers such as glucose level, blood pressure, body weight, cholesterol levels, and albuminuria has been the main focus to slow cardiovascular and renal risk among patients with diabetes. Among the agents used, those that interrupt the renin-angiotensin-aldosterone system (RAAS) have shown protection that extends beyond decreasing blood pressure. In part, these additional effects may be explained by a decrease in albuminuria.(1) Therefore, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II-receptor blockers (ARBs) have become first-choice drugs in patients with diabetes. Despite some success, the residual cardiovascular and renal risk among patients with diabetes remains . . .
PMID: 24206456 [PubMed - as supplied by publisher]